Novo Nordisk (NYSE: NVO) advances DKK 15B buyback, 24M B shares repurchased
Rhea-AI Filing Summary
Novo Nordisk A/S provides an update on its ongoing share repurchase activity conducted under EU Market Abuse Regulation safe harbour rules. As part of an overall programme to repurchase up to DKK 15 billion of B shares during the 12-month period beginning 4 February 2026, the company initiated a specific programme on 6 May 2026 to buy back B shares for up to DKK 11,200,000,010.45 through 1 February 2027. Including purchases from 6–10 July 2026, a total of 9,225,000 B shares have been repurchased under this programme for DKK 2,734,545,468. Novo Nordisk now holds 41,169,480 B shares as treasury shares, equal to 0.9% of the share capital, out of total A and B shares of 4,465,000,000. Since 4 February 2026, the company has repurchased 23,984,179 B shares at an average price of DKK 272.45 per share, corresponding to a total transaction value of DKK 6,534,545,458.
Positive
- None.
Negative
- None.
Filing Explained
Novo Nordisk has repurchased DKK 6,534,545,458 under a DKK 15 billion program and holds 0.9% of share capital as treasury shares.
Form 6-K is an interim report in which a foreign private issuer furnishes material information published in its home market, and this
As of
The filing therefore documents repurchases already made and treasury shares held, while the
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
July 13, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 6 July 2026, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement | 8,250,000 | 2,419,775,981 | |
| 6 July 2026 | 195,000 | 323.77 | 63,135,020 |
| 7 July 2026 | 195,000 | 327.75 | 63,910,282 |
| 8 July 2026 | 195,000 | 320.62 | 62,521,793 |
| 9 July 2026 | 195,000 | 320.72 | 62,540,384 |
| 10 July 2026 | 195,000 | 321.34 | 62,662,008 |
| Accumulated under the programme | 9,225,000 | 2,734,545,468 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 41,169,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 10 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 23,984,179 B shares at an average share price of DKK 272.45 per B share equal to a transaction value of DKK 6,534,545,458.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Ida Schaap Melvold | Sina Meyer |
| +45 3077 5649 | +45 3079 6656 |
| idmg@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 3444 2613 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | Mads Berner Bruun |
| +1 609 613 0568 | +45 3075 2936 |
| fptr@novonordisk.com | mbbz@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 42/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: July 13, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |